Debt-to-equity of Nurix Therapeutics, Inc. from 31 May 2021 to 30 Nov 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nurix Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 May 2021 to 30 Nov 2025.
  • Nurix Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Nov 2025 was 31%, a 20% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 31% -7.6% -20% 30 Nov 2025
Q3 2025 31% -20% -39% 31 Aug 2025
Q2 2025 30% -22% -42% 31 May 2025
Q1 2025 32% -22% -41% 28 Feb 2025
Q4 2024 39% -4% -9.2% 30 Nov 2024
Q3 2024 52% +17% +48% 31 Aug 2024
Q2 2024 53% +17% +49% 31 May 2024
Q1 2024 54% +16% +41% 29 Feb 2024
Q4 2023 43% +2.9% +7.1% 30 Nov 2023
Q3 2023 35% -5.7% -14% 31 Aug 2023
Q2 2023 35% -4.4% -11% 31 May 2023
Q1 2023 38% +2.8% +7.8% 28 Feb 2023
Q4 2022 40% +4.2% +12% 30 Nov 2022
Q3 2022 41% +5.4% +15% 31 Aug 2022
Q2 2022 40% +3.6% +10% 31 May 2022
Q1 2022 35% 28 Feb 2022
Q4 2021 36% 30 Nov 2021
Q3 2021 35% 31 Aug 2021
Q2 2021 36% 31 May 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.